This activity was planned to introduce physicians and providers to the robust data behind lipoprotein(a) as an important risk factor for atherosclerotic cardiovascular disease (ASCVD). The current guideline on the management of blood cholesterol and the current primary prevention guideline include Lp(a) as an ASCVD risk-enhancing factor. This activity will increase provider awareness and knowledge of this unique ASCVD risk factor. This case was created in response to the 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease.
CME and MOC Information
Accreditation
Physicians
The American College of Cardiology Foundation (ACCF) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The ACCF designates this enduring material for a maximum of up to .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.
MOC
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Target Audience
This activity is intended for cardiovascular adult physicians, cardiovascular pediatric physicians, cardiac surgeons, internists, family physicians, registered nurses, APRNs, and physician assistants.
Important Dates
Date of Release: October 31, 2019
Term of Approval/Date of CME/CE Expiration: October 31, 2022
Learner Objectives
Upon completion of this program, you should be able to:
- Summarize the importance of lipoprotein(a) [Lp(a)] in atherosclerotic cardiovascular disease (ASCVD) risk assessment and the importance of determining blood cholesterol management options.
- Identify elevated Lp(a) as an ASCVD risk enhancer according to the 2018 Guideline on the Management of Blood Cholesterol.
- Discuss treatment options and long-term risks associated with elevated Lp(a)
Method of Participation and CME Certificate
Requesting AMA PRA Category 1 CME Credit™ and Continuing Education credit for this Activity
To request credit, you must:
- Read all text and view all tables and/or figures in the case for which you wish to receive credit.
- Answer the questions in each case for which you wish to claim credit. After you have answered all the questions, click on the Exam Summary button. A Claim Credit button will appear on this page if you have achieved a passing score of 70% or better. If you did not achieve a passing score, please click the Reset Scores link and retake the exam.
- Click the Claim Credit button and answer the evaluation questions in the pop-up window.
- Enter the total amount of time you actually spent in the activity in the box provided. Please note that you may only claim once for each module in this activity. Click Submit.
- You will receive a message that your request has been submitted and a link to view your certificate. You may view and download the certificate when you receive the message, you may also view it at any time in the My Transcript section of My ACC.
This CME-certified activity may contain links to other educational resources such as clinical trial summaries, journal articles, guidelines, etc., that may not be CME-certified. Please note that clicking on the links provided to view these resources will open new windows, which are outside of this CME-certified activity.
Authors:
Deborah Croy, DNP, ANP-BC, AGPCNP-BC, CLS, FNLA, AACC
Dave L. Dixon, PharmD, FACC
Gina Price Lundberg, MD, FACC